Thor Medical ASA – Share capital increase in relation to the Private Placement and the PrimaryBid Offering is registered

Oslo, Norway, 26 June 2025: Reference is made to stock exchange announcement by Thor Medical ASA (the "Company") on 18 June 2025 regarding the successful completion of a private placement of a total of 30,000,000 new shares in the Company raising a total of NOK 75 million in gross proceeds (the "Private Placement") and a retail offering of a total of 4,577,399 new shares raising a total of approx. NOK 11.4 million in gross proceeds (the "PrimaryBid Offering").

 

The share capital increase relating to the Private Placement and the share capital increase relating to the PrimaryBid Offering is now registered with the Norwegian Register of Business Enterprises. The Company's share capital is after the registration NOK 69,797,184 divided into 348,985,920 shares. Each share has a nominal value of NOK 0.20 and represents one vote in the Company's general meeting.

 

DISCLOSURE REGULATION

 

This information is required to be disclosed under Section 5-12 of the Securities Trading Act.

 

CONTACTS

 

Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.com

 

ABOUT THOR MEDICAL ASA

 

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.